Hercules Capital: Kellerhals Carrard with MoonLake on debt funding by Hercules Capital

Kellerhals Carrard advised Swiss clinical-stage biotechnology company MoonLake Immunotherapeutics on its agreement with American venture lending specialist Hercules Capital for up to $500 million in non-dilutive capital, with an initial $75 million drawn at closing. Pursuant to the deal, additional tranches will become available upon achievement of certain pre-specified milestones in alignment with MoonLake's strategy [...]L'articolo Kellerhals Carrard with MoonLake on debt funding by Hercules Capital proviene da Legalcommunity.ch.